Anti‐cancer combination therapy by co‐delivery of hydrophilic and hydrophobic using dual temperature and pH‐responsive liposomes

Nezhadali, Azizollah; Shapouri, Mahmoud Reza; Amoli‐Diva, Mitra

doi:10.1049/mnl.2020.0389

Cited by 7 publications

(6 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given the limitations in combination chemotherapy, nanocarriers have become powerful vehicles for the co-delivery of different drugs [9][10][11][12][13]. In the last few decades, nanocarriers of different materials, such as liposomes [14,15], micelles [16,17] and mesoporous silica [18], have been developed to co-deliver hydrophobic/hydrophilic drugs. However, many of these encapsulate drugs noncovalently, which may lead to inaccurate drug loading and inevitably premature drug leakage during blood circulation [19].…”

Section: Introductionmentioning

confidence: 99%

Affibody Modified G-quadruplex DNA Micelles Incorporating Polymeric 5-Fluorodeoxyuridine for Targeted Delivery of Curcumin to Enhance Synergetic Therapy of HER2 Positive Gastric Cancer

Zhang

et al. 2022

Nanomaterials

View full text Add to dashboard Cite

Combination chemotherapy is emerging as an important strategy for cancer treatment with decreased side effects. However, chemotherapeutic drugs with different solubility are not easy to realize co-delivery in traditional nanocarriers. Herein, an affibody modified G-quadruplex DNA micellar prodrug (affi-F/GQs) of hydrophilic 5-fluorodeoxyuridine (FUdR) by integrating polymeric FUdRs into DNA strands is developed for the first time. To achieve synergistic efficacy with hydrophobic drugs, curcumin (Cur) is co-loaded into affi-F/GQs micelles to prepare the dual drug-loaded DNA micelles (Cur@affi-F/GQs), in which affibody is employed as a targeting moiety to facilitate HER2 receptor-mediated uptake. Cur@affi-F/GQs have a small size of approximately 130 nm and exhibit excellent stability. The system co-delivers FUdR and Cur in a ratiometric manner, and the drug loading rates are 21.1% and 5.6%, respectively. Compared with the physical combination of FUdR and Cur, Cur@affi-F/GQs show higher cytotoxicity and greater synergistic effect on HER2 positive gastric cancer N87 cells. Surprisingly, Cur@affi-F/GQs significantly enhance the expression and activity of apoptosis-associated proteins in Bcl-2/Bax-caspase 8, 9-caspase 3 apoptotic pathway, which is the main factor in the death of tumor cells induced by FUdR. Overall, this nanoencapsulation is a promising candidate for the targeted co-delivery of drugs with significant differences in solubility.

show abstract

Section: Introductionmentioning

confidence: 99%

Affibody Modified G-quadruplex DNA Micelles Incorporating Polymeric 5-Fluorodeoxyuridine for Targeted Delivery of Curcumin to Enhance Synergetic Therapy of HER2 Positive Gastric Cancer

Zhang

et al. 2022

Nanomaterials

View full text Add to dashboard Cite

show abstract

“…[ 96 ] They undergo a phase transitions at specific temperatures for controlled drug release or targeted delivery. [ 97 ]…”

Section: Ultrasound‐sensitive Intelligent Nanosystemsmentioning

confidence: 99%

Ultrasound‐Sensitive Intelligent Nanosystems: A Promising Strategy for the Treatment of Neurological Diseases

Pan,

Huang,

Nie

et al. 2023

Advanced Materials

View full text Add to dashboard Cite

Neurological diseases are a major global health challenge, affecting hundreds of millions of people worldwide. Ultrasound therapy plays an irreplaceable role in the treatment of neurological diseases due to its non‐invasive, highly focused, and strong tissue penetration capabilities. However, the complexity of brain and nervous system and the safety risks associated with prolonged exposure to ultrasound therapy severely limit the applicability of ultrasound therapy. Ultrasound‐sensitive intelligent nanosystems (USINs) are a novel therapeutic strategy for neurological diseases that bring greater spatiotemporal controllability and improved safety to overcome these challenges. This review provides a detailed overview of therapeutic strategies and clinical advances of ultrasound in neurological diseases, focusing on the potential of USINs‐based ultrasound in the treatment of neurological diseases. Based on the physical and chemical effects induced by ultrasound, rational design of USINs is a prerequisite for improving the efficacy of ultrasound therapy. Recent developments of ultrasound‐sensitive nanocarriers and nanoagents are systemically reviewed. Finally, the challenges and developing prospects of USINs are discussed in depth, with a view to providing useful insights and guidance for efficient ultrasound treatment of neurological diseases.This article is protected by copyright. All rights reserved

show abstract

“…Another interesting development is combining pH-sensitivity with other stimuli (i.e., dual/multi-stimuli responsive NPs); NPs responsive to more than one trigger offer an efficient delivery to the targeted sites with highly controlled drug release and reduced systematic toxicity. Nezhadali et al [ 82 ] synthesized pH and temperature-responsive liposomes encapsulating DOX and mitomycin C. The maximum release (98%) from the developed system was obtained at 40 °C and pH 5.5; only 15% was released at 37°C and physiological pH (7.4). In another study, Luo et al [ 83 ] combined NIR phototherapy and chemotherapy to enhance the anti-cancer effects of gold nanoshells coated liposomes.…”

Section: Challenges and Opportunitiesmentioning

confidence: 99%

pH-Responsive Nanocarriers in Cancer Therapy

et al. 2022

View full text Add to dashboard Cite

A number of promising nano-sized particles (nanoparticles) have been developed to conquer the limitations of conventional chemotherapy. One of the most promising methods is stimuli-responsive nanoparticles because they enable the safe delivery of the drugs while controlling their release at the tumor sites. Different intrinsic and extrinsic stimuli can be used to trigger drug release such as temperature, redox, ultrasound, magnetic field, and pH. The intracellular pH of solid tumors is maintained below the extracellular pH. Thus, pH-sensitive nanoparticles are highly efficient in delivering drugs to tumors compared to conventional nanoparticles. This review provides a survey of the different strategies used to develop pH-sensitive nanoparticles used in cancer therapy.

show abstract

Anti‐cancer combination therapy by co‐delivery of hydrophilic and hydrophobic using dual temperature and pH‐responsive liposomes

Cited by 7 publications

References 33 publications

Affibody Modified G-quadruplex DNA Micelles Incorporating Polymeric 5-Fluorodeoxyuridine for Targeted Delivery of Curcumin to Enhance Synergetic Therapy of HER2 Positive Gastric Cancer

Affibody Modified G-quadruplex DNA Micelles Incorporating Polymeric 5-Fluorodeoxyuridine for Targeted Delivery of Curcumin to Enhance Synergetic Therapy of HER2 Positive Gastric Cancer

Ultrasound‐Sensitive Intelligent Nanosystems: A Promising Strategy for the Treatment of Neurological Diseases

pH-Responsive Nanocarriers in Cancer Therapy

Contact Info

Product

Resources

About